本期配图来自2024年3月30日发表在Journal of Advanced Research（IF=12.8）上的文章《Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction》
- Erianin significantly alleviates breast cancer-induced osteolysis in vivo.
- 62.5–250 nM Erianin inhibits 231 CM and RANKL-activated osteoclastiesis.
- Erianin interacts with NFATc1 but not with SRC proteins to inhibit osteoclast production.
- Erianin inhibits excessive osteoclast formation in breast cancer patients.
conclusion
Erianin is an NFATc1 inhibitor that attenuates breast cancer-induced osteoclasties and bone destruction.
Background supplements
Breast cancer-associated bone metastases can lead to bone-related events (SREs) that reduce the quality of life of patients. Inhibition of osteoclast production is a key treatment for SRE, however, the availability of clinical drugs remains limited, all of which disrupt physiological bone formation while not improving patient survival.
Bibliography:
Zheng J, He W, Chen Y, Li L, Liang Q, Dai W, Li R, Chen F, Chen Z, Tan Y, Li X. Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction. J Adv Res. 2024 Mar 30:S2090-1232(24)00121-8. doi: 10.1016/j.jare.2024.03.021. Epub ahead of print. PMID: 38556044.
Yimaitong is a professional online doctor platform, and the mission of the platform is to "sense the pulse of the world's medicine and help China's clinical decision-making". Yimaitong has a series of products such as "Clinical Guidelines", "Medication Reference", "Medical Literature King", "Yizhiyuan", "eYantong" and "ePulse", which fully meet the needs of medical workers in clinical decision-making, obtaining new knowledge and improving scientific research efficiency.
This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.